A Phase II Study of Weekly Maintenance Bortezomib and Rituximab in Mantle Cell Lymphoma Post Autologous Hematopoietic Cell Transplantation.

Trial Profile

A Phase II Study of Weekly Maintenance Bortezomib and Rituximab in Mantle Cell Lymphoma Post Autologous Hematopoietic Cell Transplantation.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Mar 2017

At a glance

  • Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Rituximab (Primary)
  • Indications Mantle-cell lymphoma
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 28 Feb 2017 Status changed from recruiting to active, no longer recruiting.
    • 09 Jun 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2017.
    • 08 Dec 2015 Interim analysis results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top